BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Recruiting

Phase 1

Phase 2

BI-1808 & PembrolizumabBI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Sponsor:

BioInvent International AB

Code:

NCT04752826

Conditions

Advanced Malignancies

Ovarian Cancer

T-cell Lymphoma

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BI-1808

Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by BioInvent International AB on 2025-02-06.